title: Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program.
abstract: BACKGROUND
  Measles control has succeeded worldwide, and many countries have substantially reduced incidence and mortality. This has led to consideration of the feasibility of measles elimination in Uganda within the context of global eradication. Before an elimination program is initiated, it is important to consider its potential economic impact, including its cost-effectiveness.
  
  
  METHODS
  Incremental cost-effectiveness ratios (ICERs) were estimated for measles mortality reduction and measles elimination in Uganda. A dynamic age-structured compartmental model of measles transmission was used to simulate scenarios and estimate health outcomes and costs. The main outcome measures were costs, measles cases, measles deaths, disability-adjusted life-years (DALYs), and ICERs measured as cost per DALY averted through either the year 2030 or 2050.
  
  
  RESULTS
  Measles elimination by 2020 averted 130,232 measles cases, 3520 measles deaths, and 106,330 DALYs through the year 2030, compared with the next best scenario (95% mortality reduction by 2015), and it was the most cost-effective strategy, with ICERs of $556 per DALY averted (2030 time horizon) and $284 per DALY averted (2050 time horizon).
  
  
  CONCLUSIONS
  Measles elimination in Uganda, as part of a global eradication program, is projected to be highly cost-effective and should be considered among the available policy options for dealing with the disease.
authors.affiliation: Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195-7630, USA. babijo@uw.edu
authors.forename: Joseph B
authors.initials: JB
authors.lastname: Babigumira
authors.forename: Ann
authors.initials: A
authors.lastname: Levin
authors.forename: Colleen
authors.initials: C
authors.lastname: Burgess
authors.forename: Louis P
authors.initials: LP
authors.lastname: Garrison
authors.forename: Chris T
authors.initials: CT
authors.lastname: Bauch
authors.forename: Fiona
authors.initials: F
authors.lastname: Braka
authors.forename: William B
authors.initials: WB
authors.lastname: Mbabazi
authors.forename: Juliet O
authors.initials: JO
authors.lastname: Nabyonga
authors.forename: Emily
authors.initials: E
authors.lastname: Simons
authors.forename: Alya
authors.initials: A
authors.lastname: Dabbagh
mesh_terms: D003362:Cost-Benefit Analysis; D014943:Global Health; D006801:Humans; D017589:Immunization Programs / Q000191:economics / Q000458:organization & administration*; D015994:Incidence; D007391:International Cooperation; D008457:Measles / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000191:economics / Q000276:immunology*; D018803:Models, Economic; D014454:Uganda / Q000453:epidemiology
chemical_list: D008458:Measles Vaccine